Dr. Mahdi Basha, D.O. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 33080 Utica Rd, Fraser, MI 48026 Phone: 586-296-7250 Fax: 586-296-7256 |
James R Valice, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 33080 Utica Rd, Fraser, MI 48026 Phone: 586-296-7250 Fax: 586-296-0276 |
Norbert P Czajkowski, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: 33080 Utica Rd, Fraser, MI 48026 Phone: 586-296-7250 Fax: 586-296-0276 |
Lucas Bonafede, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 33080 Utica Rd Ste B, Fraser, MI 48026 Phone: 586-296-7250 Fax: 586-296-0276 |
Patrick M Verb, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 33080 Utica Rd, Fraser, MI 48026 Phone: 586-296-7250 Fax: 586-296-7256 |
News Archive
Infants and very young children who are exposed to anesthesia may experience higher rates of learning disabilities and cognitive difficulties than children who are not exposed to anesthesia, according to research and emerging data presented during the SmartTots: Pediatric Anesthesia Neurotoxicity panel at the International Anesthesia Research Society annual meeting in Vancouver, B.C.
Blood and Marrow Transplantation (BMT) is a potentially curative treatment for patients with leukemia or other life-threating blood diseases. With a goal of increasing survival rates, a research team led by Roswell Park Cancer Institute investigators verified patient outcome data submitted by more than 150 U.S. transplant centers over an 11-year period to the Center for International Blood and Marrow Transplant Research.
Emerging Healthcare Solutions, Inc. announced today that the company has successfully completed the due diligence and review requirements under their recent option agreement with ThromboVision, a company that has licensed the patent on the new T-GuideĀ® Platelet Function Analyzer, which is currently going through regulatory clearance review.
ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed, fully synthetic therapeutic vaccines against cancer and persistent viral infections, today announced the initiation of a Phase I/II clinical study of its lead candidate ISA101 in HIV-positive men suffering from anal intraepithelial neoplasia.
Nasal saline and corticosteroid sprays are pretty standard treatment for individuals battling chronic rhinosinusitis.
› Verified 4 days ago